US prescription peptide providers

• October 30, 2026HHS published a notice in the Federal Register: it will not act against a state-licensed pharmacy, a federal facility or a licensed physician that compounds BPC-157, TB-500, Epitalon, MOTS-c, Semax or KPV, if 10 conditions are met. It was filed for public inspection on October 28, 2026. Source: Federal Register 2026-22192
• CommentsComments on docket HHS-OASH-2026-0496 are accepted until about November 13, 2026 (two weeks after publication); check the docket for the exact closing date. Sources: Federal Register notice, regulations.gov
• ConditionsA patient-specific prescription. Ingredient from a maker registered with FDA, with a test certificate for each lot, including endotoxin. One peptide per product, so no blends. A set label. Adverse events reported to FDA. Source: HHS policy text (archived copy)
• LimitsThis is enforcement discretion. It is not FDA approval: compounded drugs are not FDA-approved. The policy is not binding and HHS may revisit it. It does not cover 503B outsourcing facilities. State rules still apply. Read the conditions

We did not take the sites at their word. For every seller we ran 3 checks of our own on October 29, 2026.

• LicenseThe pharmacy that fills the order is named, and its state board shows the license as active. 17 pass, 1 fail, 232 unknown
• PharmacyOn October 30, 2026 we searched the whole site of the 12 clinics whose pharmacy was unknown. 10 name no pharmacy anywhere public. 2 name a pharmacy, but we cannot confirm it fills their peptides. We also looked up each named prescriber in the NPI registry. Their license checks stay unknown.
• CheckoutWe added the peptide to the cart and stopped at the first step. Pass means a medical step comes before any payment. 179 pass, 2 fail, 69 unknown
• WordingNo “research use only” or “not for human consumption” text on the pages that sell it. 195 pass, 10 fail, 45 unknown

We never made an account, typed personal data or paid. Unknown means we could not reach that step.